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Abstract
Background:  Craniosynostosis, the premature fusion of calvarial sutures, is a common
craniofacial abnormality. Causative mutations in more than 10 genes have been identified, involving
fibroblast growth factor, transforming growth factor beta, and Eph/ephrin signalling pathways.
Mutations affect each human calvarial suture (coronal, sagittal, metopic, and lambdoid) differently,
suggesting different gene expression patterns exist in each human suture. To better understand the
molecular control of human suture morphogenesis we used microarray analysis to identify genes
differentially expressed during suture fusion in children with craniosynostosis. Expression
differences were also analysed between each unfused suture type, between sutures from syndromic
and non-syndromic craniosynostosis patients, and between unfused sutures from individuals with
and without craniosynostosis.
Results: We identified genes with increased expression in unfused sutures compared to fusing/
fused sutures that may be pivotal to the maintenance of suture patency or in controlling early
osteoblast differentiation (i.e. RBP4, GPC3, C1QTNF3, IL11RA, PTN, POSTN). In addition, we have
identified genes with increased expression in fusing/fused suture tissue that we suggest could have
a role in premature suture fusion (i.e. WIF1, ANXA3, CYFIP2). Proteins of two of these genes,
glypican 3 and retinol binding protein 4, were investigated by immunohistochemistry and localised
to the suture mesenchyme and osteogenic fronts of developing human calvaria, respectively,
suggesting novel roles for these proteins in the maintenance of suture patency or in controlling
early osteoblast differentiation. W e  s h o w  t h a t  t h e r e  i s  l i m i t ed difference in whole genome
expression between sutures isolated from patients with syndromic and non-syndromic
craniosynostosis and confirmed this by quantitative RT-PCR. Furthermore, distinct expression
profiles for each unfused suture type were noted, with the metopic suture being most disparate.
Finally, although calvarial bones are generally thought to grow without a cartilage precursor, we
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show histologically and by identification of cartilage-specific gene expression that cartilage may be
involved in the morphogenesis of lambdoid and posterior sagittal sutures.
Conclusion: This study has provided further insight into the complex signalling network which
controls human calvarial suture morphogenesis and craniosynostosis. Identified genes are
candidates for targeted therapeutic development and to screen for craniosynostosis-causing
mutations.
Background
Calvarial bones form by the proliferation and differentia-
tion of multipotent mesenchymal cells into osteoblasts.
This process, known as intramembranous ossification, is
distinct from the development of the majority of other
bones in the body which form by the ossification of a pre-
existing cartilaginous matrix (endochondral ossification).
Calvaria first form from a condensation of mesenchyme
termed the primary centre of ossification. Mesenchymal
cell proliferation and subsequent differentiation into
osteoblasts occurs at the margins and the bone grows in a
radial fashion until the osteogenic fronts of two calvaria
approximate each other and structures called sutures form
between the bones [1]. These intervening fibrous sutures
act as flexible joints between the developing bones allow-
ing the skull to change shape and grow during develop-
ment. Maintenance of growth at the osteogenic fronts at
the edges of the sutures requires a fine balance between
proliferation and differentiation. Additionally, apoptosis
has a role ensuring that the two osteogenic fronts remain
separated [2]. Disruption of any of these processes can
result in the premature fusion of calvarial sutures, known
as craniosynostosis.
Craniosynostosis is amongst the most common cranial
defects, second only to cleft palate. It occurs in 1 in 2500
live births and can be associated with significant morbid-
ity, including mental retardation, deafness, and blindness,
in addition to the significant social stigma associated with
craniofacial deformation [3]. The condition may be
caused by various genetic mutations, exposure to tera-
togens such as retinoic acid, mechanical stress, or result
from certain metabolic or haematologic disorders [4,5].
Non-syndromic craniosynostosis refers to sporadic suture
fusion in the absence of other developmental abnormali-
ties and most commonly affects the sagittal suture. Syn-
dromic craniosynostosis occurs as a result of simple
genetic mutations and is accompanied by additional
developmental abnormalities particularly involving the
limbs [6]. Syndromic forms of craniosynostosis com-
monly affect the coronal suture but other sutures may be
affected depending on the underlying genetic mutation.
FGFR2 mutations are the most common and most severe
affecting the coronal, metopic, sagittal, and lambdoid
sutures.  FGFR3  mutations affect the coronal and/or
metopic sutures. FGFR1, TWIST1 and EFNB1 mutations
generally affect only the coronal suture. FNB1  and
TGFBR1 mutations have been associated with synostosis
of the sagittal and/or lambdoid sutures, while gain-of-
function MSX2 mutations result in synostosis of the coro-
nal and sagittal sutures (reviewed in [7]).
The large number of genes identified as causal for cranio-
synostosis suggests that a complex molecular network
controls suture morphogenesis in humans. In addition,
rodent studies have revealed a role in suture formation for
transforming growth factor beta (TGFβ) signalling medi-
ated by various bone morphogenetic proteins (BMPs) [8-
11]. Targeted functional genetic approaches are slowly
unravelling the molecular signalling that controls suture
morphogenesis. However, there is also a need for a broad
experimental approach aimed at identifying all genes and,
subsequently, their associated pathways which are essen-
tial to suture morphogenesis.
The different phenotypes induced by the known muta-
tions suggest that distinct molecular pathways may be
operating in different sutures. This is particularly evident
in the case of the metopic suture which, in humans, nor-
mally fuses shortly after birth, while the other sutures
remain patent until adulthood. This feature of the
metopic suture may be explained by the finding in
rodents that the frontal suture (equivalent to the metopic
suture in humans) is populated by neural crest derived
mesenchyme and separates the frontal bones, also of neu-
ral crest origin, while the other sutures are a juxtaposition
of neural crest and paraxial mesoderm [12-14]. To under-
stand the mechanisms of the fusion process gene expres-
sion profiles between the fusing posterior frontal sutures
in mice have been compared to profiles from unfused sag-
ittal and coronal sutures [15-20]. However, given that the
signalling pathways controlling suture fusion are likely to
differ in sutures derived from different developmental ori-
gins, it is unclear what such comparisons tell us about
these fusion processes. There is, therefore, a need to study
differential gene expression between fused and unfused
sutures of the same developmental origin.
Subtle differences in cranial biology also exist between
rodents and humans. For example, the rodent model cre-
ated for the Pro250Arg FGFR1 mutation, which causes
Pfeiffer syndrome, develops synostosis of the frontal, sag-BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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ittal and coronal sutures [21] whereas in humans this
mutation commonly affects only the coronal suture. Fur-
thermore, primary cells cultured from patients with
FGFR2  mutations and mice generated with the same
mutations show differing proliferation and differentiation
characteristics (reviewed in [22]). These differences
emphasise that mechanisms controlling rodent suture
morphogenesis do not exactly mimic those occurring in
human sutures.
In this study we have analysed global in vivo expression
differences between fused, fusing, and unfused sutures
from patients with craniosynostosis to identify genes
which are involved in maintaining suture patency and
driving suture fusion within each human suture.
Results
Five patients were recruited to the gene identification
stage of this study, one diagnosed with syndromic cranio-
synostosis (Apert syndrome [MIM 101200]) and four
with non-syndromic craniosynostosis (Table 1). Sixteen
suture samples were obtained from these patients for
microarray analysis; nine from unfused sutures, two from
fusing, and five from fused sutures (Fig. 1A). To minimise
any age-related changes and to eliminate any sex-related
effects on the development of craniosynostosis, sutures
were obtained from males aged 3-7 months. The stage of
fusion was confirmed by 3D computer tomography (CT),
MicroCT, and histological analysis and classified as
unfused, fusing, or fused (Fig. 1). We performed microar-
ray analyses on RNA isolated from sutures resected at sur-
gery using the Affymetrix Human U133A 2.0 GeneChip
platform containing ~18,000 gene transcripts. Microarray
data were initially assessed using a number of quality con-
trol measures (Additional files 1, 2, 3). RNA digestion
plots indicated that all samples showed a high similarity
in RNA quality except for one unfused sagittal sample
from patient #36 (US36). NUSE and Mbox plots indicated
that this sample had a similar expression intensity com-
pared to other samples but had elevated standard errors.
We were initially cautious in our interpretation of any par-
ticular difference in expression seen with this sample.
Patient genetic background does not adversely affect gene 
expression
Hierarchical clustering, based on whole genome expres-
sion, showed samples typically grouped according to stage
of fusion or suture type, and not solely by patient of ori-
gin, indicating no adverse patient-specific genetic back-
ground biases existed (Additional file 4). Importantly,
sutures from the Apert syndrome patient grouped more
closely with similar sutures from other non-syndromic
patients, than they did to each other. These similarities in
gene expression between syndromic and non-syndromic
patients were confirmed with additional syndromic sam-
ples using realtime quantitative RT-PCR (qRT-PCR), as
described later. This indicates that patient genetic back-
ground does not overly impact on gene expression and it
provides proof of principle that the combined analysis of
syndromic and non-syndromic patient samples can be
applied in the study of general mechanisms of craniosyn-
ostosis.
Metopic sutures have different gene expression profiles to 
other sutures
The neural crest origin of the metopic suture mesen-
chyme, compared to the predominantly mesodermal ori-
gin of the other sutures may result in the metopic suture,
exhibiting significantly different expression profiles to the
other suture types. We therefore initially analysed differ-
ential gene expression between fused and unfused sutures
treating metopic sutures separately. Microarray expression
data were combined for all unfused (n = 8) and all fusing/
fused (n = 6) sutures, from the sagittal, coronal and lamb-
doid sutures and differential expression was analysed
between the two groups. Initially, a subset of differentially
expressed probe sets was selected based on those with a
multiple testing corrected P < 0.1 (n = 84) in order to
assess how well the analysis separated the two groups of
interest. This minimally-selective P-value was chosen to
remove a large number of those genes which were not
modulated in the two tissue types. Pair-wise correlation of
all samples to an arbitrarily chosen unfused suture sample
(#36 non-syndromic, unfused coronal) showed that sam-
ples were separated based on stage of fusion using the
chosen gene subset, with a gradient of relatedness seen for
unfused, fusing, and fused tissues (Fig. 2A). Furthermore,
the unfused metopic suture grouped with the fused tis-
sues, suggesting that metopic suture mesenchyme has an
expression profile more similar to fused tissue. This result
vindicated our exclusion of metopic suture samples from
statistical analyses of differential expression between
unfused and fused samples. All other unfused sutures
showed a very high correlation in expression between
themselves, whereas fused and fusing sutures were more
disparate in expression profiles. This broader distribution
of fusing and fused sutures may indicate that they were
undergoing pathologic fusion of different aetiologies and/
or that they were at different stages of the fusion process.
Additionally, there was evidence for suture-specific
expression, with the unfused sagittal sutures being slightly
less correlated to unfused coronal sutures than were
unfused lambdoid sutures. This difference was later ana-
lysed by comparing expression solely between each
unfused suture type; however by pooling unfused sutures
for the initial analyses we were also able to identify those
genes commonly involved in morphogenesis of all
sutures.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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Hierarchical clustering based on the selected subset of
genes clearly showed that suture tissue samples formed
two clusters, mirroring two states of fusion: fused/fusing
and unfused (Fig. 2B). This suggests that fusing sutures are
generally more similar to fused than unfused sutures and
that it is appropriate to group them together for analyses.
It was also noted that in both plots in Figure 2, sample
US36, despite RNA quality concerns, grouped most
closely with the other unfused sagittal suture and thus it
was appropriate to include this sample in further analyses.
Table 1: Phenotypes of patients, identified causative mutations, fusion state and site of obtained sutures.
Analysis Patient Phenotype Sex Age (m) Mutation Fused Suture Fusing Suture Unfused Suture
Microarray #42 Apert syndrome M 7 FGFR2 Ser252Trp Coronala
Lambdoida
Metopica
#36 Unicoronal 
synostosis
M 3 No FGFR or TWIST1 Coronala Coronala
Sagittal
#46 Sagittal synostosis M 5 No FGFR or TWIST1 Sagittal Coronal
Lambdoida
Metopica
#50 Sagittal synostosis M 6 No FGFR or TWIST1 Sagittal Coronal
#58 Sagittal synostosis M 7 No FGFR or TWIST1 Sagittala Sagittalb Sagittala
Coronal
Lambdoida
Validation #47 Apert syndrome F 38 FGFR2 Pro253Arg Metopic
#85 Apert syndrome F 40 FGFR2 Ser252Trp Sagittal Metopic
#90 Apert syndrome F 4 FGFR2 Pro253Arg Coronal Coronalc Sagittal
Metopic
#61 Apert syndrome M 20 FGFR2 Ser252Trp Coronal Coronal
#92 Muenke syndrome F 6 FGFR3 Pro250Arg Coronal
#104 Saethre-Chotzen 
syndrome
M 14 TWIST1 c.256_276dup Sagittal
Metopic
#49 Metopic synostosis M 10 No FGFR or TWIST1 Metopic
#60 Sagittal synostosis F 9 No FGFR or TWIST1 Sagittal Sagittal
#63 Sagittal synostosis M 10 No FGFR or TWIST1 Sagittal Sagittal Lambdoid
#72 Lambdoid synostosis M 26 No FGFR or TWIST1 Lambdoid
#91 Sagittal synostosis F 5 No FGFR or TWIST1 Metopic
#94 Metopic synostosis F 9 No FGFR or TWIST1 Metopic Metopic Sagittal
#95 Unicoronal 
synostosis
M 5 No FGFR or TWIST1 Coronal
#41 Normal – Tessier 
Cleft
F 91 Not tested Metopic
#69 Normal – 
hydrocephalus
F 4 Not tested Lambdoid
#73 Normal – cerebellar 
tumour
M 9 Not tested Coronal
#81 Normal – 
hydrocephalus
F 2 Not tested Lambdoid
#87 Normal – cerebellar 
tumour
M 57 Not tested Coronal
#89 Normal – 
hydrocephalus
M 1 day Not tested Lambdoid
Histology #3 Apert syndrome M 4 FGFR2 Ser252Trp Lambdoid
#5 Sagittal synostosis M 3 No FGFR or TWIST1 Sagittal
#80 Metopic synostosis M 6 No FGFR or TWIST1 Coronal
Sagittal
#83 Sagittal synostosis M 6 No FGFR or TWIST1 Lambdoid (x2) 
Coronal
#84 Unicoronal 
synostosis
F 7 No FGFR or TWIST1 Coronal Sagittal
aRNA sample also used for qRT-PCR validation experiments.
bSample used for validation experiments, but not microarray analysis.
cTwo samples of varying degrees of fusion were obtained. The sample which was at the earlier stage of fusion was used for validation qRT-PCR; the 
sample at a later stage of fusion was used for within patient comparison only.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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Genes differentially expressed between fused and unfused 
sutures
Based on a linear regression analysis of genes differen-
tially expressed between the unfused group of sutures and
the group of fusing/fused sutures, 28 genes were signifi-
cantly (multiple testing corrected P < 0.05) differentially
expressed (Table 2). Irrespective of P-value, a greater than
2-fold expression difference was found for 829 probe sets;
252 were "increased" and 577 were "decreased" in
unfused compared to fusing/fused sutures (Additional file
5). Amongst those genes increased in unfused sutures
were FGFR2, TGFB2, and epidermal growth factor receptor
(EGFR) (Table 3). All have been previously linked with
calvarial development and, in the case of FGFR2, with
craniosynostosis [23-28]. Thirty two of these 829 probe
sets (3.9%), representing 24 genes, had a significant dif-
ference in expression (multiple testing corrected P < 0.05),
suggesting that these are important in the morphogenesis
of all sutures. All, except one, were increased in unfused
sutures. The identification of such a small number of sig-
nificantly expressed genes across all suture types is likely
due to the fact that different suture types, which may have
slightly different gene expression profiles, were combined
for the analysis. As we did not want to reject any poten-
tially important genes, including those expressed to vary-
ing degrees in different sutures, we carried out further
analyses using the genes in the 2-fold list, irrespective of
their P-value. Importantly, however, we recognise that
those genes with a P < 0.05 are more likely to be key reg-
ulators of suture morphogenesis, rather than specific to
one suture type.
Computer tomography (CT) scans showing site and fusion  state of sutures obtained from craniosynostosis patients Figure 1
Computer tomography (CT) scans showing site and 
fusion state of sutures obtained from craniosynostosis 
patients. A) Posterior and superior (left and right) view of 
patient #58 indicating where unfused, fusing and fused sutures 
were obtained from. p, parietal bone; o, occipital bone; f, frontal 
bone. B) MicroCT image demonstrating a fusing and unfused 
suture. Scale 1 mm.
Microarray sample correlations based on a selected gene list (fused v unfused, P < 0.1) Figure 2
Microarray sample correlations based on a selected gene list (fused v unfused, P < 0.1). Correlations are based on genes dif-
ferentially expressed (P < 0.1) between unfused and fused sutures for combined samples from coronal, lambdoid and sagittal sutures. A) 
Correlation to the unfused coronal suture from patient #36 shows a gradient of correlation between unfused, fusing and fused sutures. 
The unfused metopic suture groups with fused sutures. Patient number is recorded below data points and state of fusion above data 
points. B) Hierarchical clustering separates suture data into unfused and fusing/fused sutures. Unfused lambdoid and coronal sutures are 
more related to each other than they are to sagittal sutures. U, unfused; Fg, fusing; F, fused; C, coronal; S, sagittal; L, lambdoid; M, 
metopic; patient number follows sample identifier.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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To further categorise the 2-fold differentially-expressed
gene list, gene ontology (GO) over-representation was
analysed. Biological processes enriched in the 2-fold gene
list are shown in Table 4. Genes with higher expression in
unfused sutures were found to significantly over-represent
processes such as mesoderm formation, skeletal develop-
ment, cell adhesion, cell surface receptor signalling, and
extracellular matrix organisation, consistent with genes
involved in regulating suture morphogenesis. Surpris-
ingly, we also noted an extremely significant over-repre-
sentation within those genes with higher expression in
fusing/fused sutures of genes involved in the response to
biotic stimuli (P = 5.73 × 10-41) and the immune
response (P = 1.61 × 10-34). As fold change is not the only
useful characteristic, GO over-representation analysis was
also conducted irrespective of fold change for all probe
sets with a minimally selective P < 0.25 (n = 261) and sim-
ilar categories were identified.
Gene Set Enrichment Analysis (GSEA) was then used to
asses the significance of this set of differentially expressed
genes at the molecular level. The ranked list of 2-fold dif-
ferentially expressed genes was compared with a curated
database consisting of molecular pathways and publicly
available microarray experiments (Additional file 6). Such
a comparison identifies which molecular pathways share
a group of genes with our identified gene list, providing a
potential insight into involved biological networks. Those
gene sets which were significantly correlated (multiple
testing corrected P < 0.05) to genes increased in unfused
sutures included genes with activating transcription factor
3 (ATF3) and lymphoid enhancer-binding factor 1 (LEF1)
binding motifs within 2 kb of their transcription start
sites, genes up-regulated by TGFβ, genes up-regulated in
haematopoietic stem cells, genes up-regulated in CD31
negative stromal stem cells which differentiate into bone
cells, and genes down-regulated upon Cytomegalovirus
(CMV) infection. This final gene set makes a connection
between those genes down-regulated during suture fusion
(i.e. up-regulated in unfused sutures) and genes down-
regulated during infection. This integrated well with the
gene sets which were significantly correlated with those
genes increased during fusion; these included genes up-
regulated in liver in graft verses host disease (GVHD; par-
ticularly genes associated with attraction and activation of
donor T-cells), genes up-regulated in pulpal tissue from
Table 2: Significantly differentially expressed genes: unfused v fusing/fused sutures.
Gene GenBank Name Fold
MFAP4 NM_002404 microfibrillar-associated protein 4 16.50
IL11RA NM_004512 interleukin 11 receptor, alpha 5.90
RBP4 NM_006744 plasma retinol binding protein 4 37.38
AMPH NM_001635 amphiphysin 8.27
INHBA NM_002192 inhibin, beta A (activin A, activin AB alpha polypeptide) 6.94
C1QTNF3 BC016021 C1q and tumor necrosis factor related protein 3 20.25
PRELP BC032498 proline arginine-rich end leucine-rich repeat protein 10.65
HDHD1A NM_012080 haloacid dehalogenase-like hydrolase domain containing 1A -1.78
AGC1 NM_013227 aggrecan 1 (chondroitin sulfate proteoglycan 1) 6.16
ANGPTL2 NM_012098 angiopoietin-like 2 6.67
C1orf24 NM_052966 chromosome 1 open reading frame 24 2.04
FMOD NM_002023 fibromodulin 5.41
OLFM1 NM_006334 olfactomedin 1 2.55
FBLN1 NM_006486 fibulin 1 12.88
SSPN NM_005086 sarcospan 4.40
CYFIP2 BC026892 cytoplasmic FMR1 interacting protein 2 -2.68
MN1 NM_002430 meningioma 1 3.72
PTN NM_002825 pleiotrophin (osteoblast-specific factor 1) 6.25
EGFR NM_005228 epidermal growth factor receptor 2.71
TNN NM_022093 tenascin N 6.67
ADCY2 NM_020546 adenylate cyclase 2 (brain) 2.96
PDZRN3 NM_015009 PDZ domain containing RING finger 3 3.71
SPON1 BC041974 spondin 1, extracellular matrix protein 4.73
APP NM_000484 amyloid beta (A4) precursor protein 1.83
AUTS2 NM_015570 autism susceptibility candidate 2 1.94
GPC3 NM_004484 glypican 3 7.13
HAPLN1 NM_001884 hyaluronan and proteoglycan link protein 1 7.10
LHX6 NM_014368 LIM homeobox 6 -1.80
Twenty-eight genes were identified as being significantly (false discovery rate adjusted P < 0.05) differentially expressed in unfused sutures compared 
to fused/fusing sutures. Genes are listed in order of significance with fold change relative to unfused sutures.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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Table 3: Selection of genes with fold change between unfused and fused sutures and between each unfused suture site.
Gene Name Affymetrix ID Description Fold U-F P-value U-F Unfused 
Lambdoid
Unfused 
Coronal
Unfused 
Sagittal
Signalling
ANGPTNL2 213004_at angiopoietin-like 2 6.67 0.024 1.00 -1.45 -2.87
EGFR 201983_s_at epidermal growth factor receptor 2.71 0.038 1.00 1.02 1.20
EPHA3 206071_s_at EPH receptor A3 2.92 0.480 1.00 -2.06 -5.33
EPHA4 206114_at EPH receptor A4 2.75 0.173 1.00 -1.19 -1.60
EPHB2 209589_s_at EPH receptor B2 2.39 0.093 1.00 1.22 -1.12
FGFR2 208228_s_at fibroblast growth factor receptor 2 3.36 0.294 1.00 -1.42 -3.72
FZD1 204451_at frizzled homolog 1 (Drosophila) 2.13 0.326 1.00 -1.08 -2.41
IL11RA 204773_at interleukin 11 receptor, alpha 5.90 0.003 1.00 1.49 1.32
TGFB2 209909_s_at transforming growth factor, beta 2 3.76 0.096 1.00 -1.01 -2.08
FGFR1 222164_at fibroblast growth factor receptor 1 1.23 0.480 1.00 -1.29 1.12
FGFR3 204379_s_at fibroblast growth factor receptor 3 1.42 0.480 1.00 1.23 1.33
WNT5A 205990_s_at wingless-type MMTV integration site family, 
member 5A
1.24 0.857 1.00 -1.03 -5.18
IL17R 205707_at interleukin 17 receptor -2.67 0.480 1.00 -1.25 3.35
OLFM4 212768_s_at olfactomedin 4 -6.69 0.480 1.00 -2.15 6.77
WIF1 204712_at WNT inhibitory factor 1 -3.19 0.480 1.00 -1.27 5.37
Structural
COL2A1 213492_at collagen, type II, alpha 1 (primary osteoarthritis) 7.21 0.390 1.00 -20.66 -3.84
COL3A1 215077_at collagen, type III, alpha 1 (Ehlers-Danlos syndrome 
type IV)
6.32 0.072 1.00 1.24 -3.84
COL8A2 221900_at collagen, type VIII, alpha 2 11.49 0.092 1.00 -1.23 -12.73
COL10A1 217428_s_at collagen, type X, alpha 1(Schmid metaphyseal 
chondrodysplasia)
14.65 0.407 1.00 -41.66 -17.28
FBLN1 202995_s_at fibulin 1 12.88 0.025 1.00 -1.39 -1.92
FMOD 202709_at fibromodulin 5.41 0.024 1.00 -1.09 -1.70
NELL2 203413_at NEL-like 2 (chicken) 6.40 0.270 1.00 -4.21 -3.01
PRELP 204223_at proline arginine-rich end leucine-rich repeat 
protein
10.65 0.009 1.00 1.20 -1.31
THBS2 203083_at thrombospondin 2 6.62 0.069 1.00 -1.26 -2.47
COL1A2 202404_s_at collagen, type I, alpha 2 1.05 0.480 1.00 -1.01 -1.06
CORO1A 209083_at coronin, actin binding protein, 1A -5.08 0.480 1.00 -1.05 11.73
Transcription
BHLH3 221530_s_at basic helix-loop-helix domain containing, class B, 3 5.95 0.093 1.00 -2.23 -4.76
CART1 206837_at cartilage paired-class homeoprotein 1 2.06 0.533 1.00 16.21 2.38
HLF 204753_s_at hepatic leukemia factor 3.54 0.210 1.00 -2.55 -6.81
JUN 201465_s_at v-jun sarcoma virus 17 oncogene homolog (avian) 4.41 0.161 1.00 3.14 2.50
PITX2 207558_s_at paired-like homeodomain transcription factor 2 3.45 0.279 1.00 1.63 -2.08
SIX2 206510_at sine oculis homeobox homolog 2 (Drosophila) 2.72 0.136 1.00 -1.09 -1.70
FOS 209189_at v-fos FBJ murine osteosarcoma viral oncogene 
homolog
1.40 0.745 1.00 14.96 4.13
FOSB 202768_at FBJ murine osteosarcoma viral oncogene homolog 
B
1.83 0.695 1.00 54.37 20.22
FOXD1 206307_s_at forkhead box D1 1.49 0.499 1.00 -4.71 -5.17
JUNB 201473_at jun B proto-oncogene 1.28 0.703 1.00 3.61 2.95
MEOX2 206201_s_at mesenchyme homeo box 2 (growth arrest-specific 
homeo box)
1.66 0.495 1.00 -3.99 -7.74
MSX2 210319_x_at msh homeo box homolog 2 (Drosophila) 1.95 0.464 1.00 -1.14 -2.23
TWIST1 213943_at twist homolog 1 (Saethre-Chotzen syndrome) 1.50 0.476 1.00 -1.20 -1.27
LHX6 219884_at LIM homeobox 6 -1.80 0.050 1.00 -1.07 -1.03
SHOX2 210135_s_at short stature homeobox 2 -3.44 0.480 1.00 -1.00 4.50
PAX5 221969_at paired box gene 5 (B-cell lineage specific activator) -4.20 0.480 1.00 -1.69 6.25
Catalytic Activity
ROR1 205805_s_at receptor tyrosine kinase-like orphan receptor 1 2.26 0.095 1.00 1.21 -1.14
HDHD1A 203974_at haloacid dehalogenase-like hydrolase domain 
containing 1A
-1.78 0.018 1.00 1.05 1.05
ALOX5 204446_s_at arachidonate 5-lipoxygenase -5.55 0.480 1.00 -1.30 6.76
ANXA3 209369_at annexin A3 -7.17 0.480 1.00 -1.30 6.76
TransporterBMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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carious teeth, and genes up-regulated during retinoic acid
induced promyelocytic differentiation. These observa-
tions are consistent with our previous GSEA observations
in a microarray comparison between fused sutures tissue
and de-differentiated explant cells, where we again found
an increase in expression of immune response genes in
fused suture tissues [29]. It is possible that these immune
response genes reflect the formation of bone marrow
within the fused bone matrix. In support of this, micros-
copy revealed a large accumulation of lymphocytes and
other white blood cells within the calvarial bones (Addi-
tional file 7). A second explanation may be that premature
fusion is functionally associated with an immune
response to infection, either directly or indirectly, as it is
known that various immunoregulatory cytokines influ-
ence bone homeostasis and that osteoblasts may facilitate
immune responses by producing immunomodulatory
molecules (reviewed in [30,31]).
Results were then analysed on a gene-based level. One of
the families of genes which were significantly over-repre-
sented in unfused sutures was Eph/ephrin signalling mol-
ecules. These form a pathway recently invoked in causing
craniosynostosis [32,33]. Specifically, we found that three
ephrin receptor genes had higher expression in unfused
sutures (EPHA3, 2.9-fold; EPHA4, 2.8-fold; EPHB2, 2.4-
fold). Multiple genes from several other gene families
were also increased in unfused sutures (Table 3). These
include small leucine-rich proteoglycans (SLRPs), a group
of secreted proteins that are known to be involved in car-
tilage and bone formation through facilitating collagen
fibril binding to the EMC [34,35] and regulating TGFβ
activity by sequestering TGFβ in the ECM, thus preventing
binding to cell surface receptors [36]. Such genes were,
proline arginine-rich end leucine-rich repeat protein (PRELP,
10.7-fold),  osteoglycin  (OGN, 5.7-fold), fibromodulin
(FMOD, 5.4-fold) and decorin (DCN, 2.0-fold).
A large over-representation of collagen genes was also
observed. In particular, collagen type II, III, VI, VIII, X, and
XI were all up-regulated in unfused sutures. Interestingly,
Collagen type II and X are generally associated with carti-
lage formation, and would not be expected to be
expressed during intramembranous ossification. How-
ever, a number of other cartilage-specific genes were also
increased in unfused sutures (AGC1,6.2-fold;  HAPLN1,
C1QTNF3 220988_s_at C1q and tumor necrosis factor related protein 3 20.25 0.007 1.00 -1.52 -4.92
RBP4 219140_s_at retinol binding protein 4 (plasma) KIAA1922 37.38 0.003 1.00 -1.35 -2.53
APOC1 204416_x_at apolipoprotein C-I -2.01 0.480 1.00 1.08 5.06
Binding
AGC1 217161_x_at aggrecan 1 (chondroitin sulfate proteoglycan 1) 6.16 0.024 1.00 -1.25 -1.56
CCND1 208711_s_at cyclin D1 2.13 0.449 1.00 1.38 2.24
GPC3 209220_at glypican 3 7.13 0.050 1.00 1.26 -3.34
HAPLN1 205523_at hyaluronan and proteoglycan link protein 1 7.10 0.050 1.00 -1.96 -4.01
INHBA 210511_s_at inhibin, beta A (activin A, activin AB alpha 
polypeptide)
6.94 0.006 1.00 -1.36 -3.03
MFAP4 212713_at microfibrillar-associated protein 4 16.50 0.001 1.00 1.32 -1.86
OGN 218730_s_at osteoglycin (osteoinductive factor, mimecan) 5.71 0.166 1.00 -1.41 -4.65
POSTN 214981_at periostin (osteoblast specific factor 2) 5.87 0.101 1.00 -1.16 -1.60
PTN 209466_x_at pleiotrophin (osteoblast specific factor 1) 6.25 0.031 1.00 -1.14 -1.78
S100A10 200872_at S100 calcium binding protein A10 (annexin II 
ligand)
2.01 0.096 1.00 -1.04 -1.60
CCND3 201700_at cyclin D3 -2.60 0.480 1.00 -1.00 3.62
FCN1 205237_at ficolin (collagen/fibrinogen domain containing) 1 -5.45 0.480 1.00 -1.46 12.39
FGR 208438_s_at Gardner-Rasheed feline sarcoma viral (v-fgr) 
oncogene homolog
-3.03 0.480 1.00 -1.13 5.75
S100A12 205863_at S100 calcium binding protein A12 (calgranulin C) -8.86 0.480 1.00 -2.63 15.19
Enzyme regulator
MMP14 202827_s_at matrix metalloproteinase 14 (membrane-inserted) 2.39 0.226 1.00 -1.22 -1.84
TIMP3 201149_s_at tissue inhibitor of metalloproteinase 3 2.22 0.467 1.00 -1.71 -3.43
CASP1 211366_x_at caspase 1, apoptosis-related cysteine protease -2.73 0.165 1.00 -1.30 1.01
MME 203434_s_at membrane metallo-endopeptidase (CD10) -3.23 0.476 1.00 -2.35 -1.29
MMP8 207329_at matrix metalloproteinase 8 (neutrophil 
collagenase)
-5.81 0.480 1.00 -2.36 1.69
RASGRP2 208206_s_at RAS guanyl releasing protein 2 (calcium and DAG-
regulated)
-2.60 0.480 1.00 1.02 3.02
Unknown Function
CYFIP2 220999_s_at cytoplasmic FMR1 interacting protein 2 -2.68 0.031 1.00 1.14 1.09
Gene expression fold change (U-F) is presented for unfused sutures (n = 8) compared to fused/fusing sutures (n = 6), with corresponding P-values, 
and for combined unfused coronal (n = 4) and unfused sagittal (n = 2) sutures compared to unfused lambdoid sutures (n = 2).
Table 3: Selection of genes with fold change between unfused and fused sutures and between each unfused suture site. (Continued)BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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7.1-fold; CART1, 2.1-fold) suggesting that there may be a
role for cartilage in calvarial suture morphogenesis. Addi-
tional secreted matrix proteins that were over-expressed in
unfused suture tissue included pleiotrophin  (PTN, also
known as osteoblast specific factor 1 (OSF1)) and periostin
(POSTN, osteoblast specific factor 2 (OSF2)). PTN has been
identified in osteoblasts undergoing early stages of differ-
entiation and is a potent regulator of osteoblast prolifera-
tion, recruitment, and differentiation [37]. POSTN is also
expressed by early osteoblasts and is a target of Twist1
transcriptional regulation in mice [38]. A number of pro-
teases and protease inhibitors were also differentially
expressed between unfused and fused suture tissue includ-
ing,  MMP2  (2.0-fold), MMP14  (2.4-fold), MMP8  (5.8-
fold),  MME  (-3.23-fold),  SERPINA1  (-2.7-fold),
SERPINB1 (-3.6-fold) and TIMP3 (2.3-fold) (Additional
file 5).
Numerous genes involved in Wnt signalling were also
identified;  glypican 3 (GPC3, 7.1-fold) and frizzled 1
(FZD1, 2.1-fold) were increased in unfused sutures, while
WNT inhibitory factor 1 (WIF1, 3.2-fold) was increased in
fused sutures. Previously, we have identified an up-regula-
tion of WIF1 in human fused suture tissue when compar-
ing in vivo expression to expression of de-differentiated
explant cells [29]. These results are consistent with the
recent observations that activation of canonical Wnt sig-
nalling is important in osteoblast expansion and differen-
tiation [39], and that antagonist of Wnt signalling are
essential to initiate terminal osteoblasts differentiation
[40].
A number of the genes differentially expressed between
fused, fusing, and unfused sutures which had a large sig-
nificant (P < 0.05) fold change (Table 2) had not been
previously identified to be expressed in human calvaria.
Of particular interest were retinol-binding protein 4 (RBP4,
37.4-fold, P = 0.003), C1q and tumour necrosis factor related
protein 3 (C1QTNF3, 20.3-fold, P = 0.007), microfibrillar-
associated protein 4 (MFAP4, 16.5-fold, P = 0.001), PRELP
(10.7-fold, P = 0.009), GPC3 (7.1-fold, P = 0.05), tenascin
N (TNN, 6.7-fold, P = 0.038), pleiotrophin (PTN, 6.3-fold,
P = 0.031) and interleukin 11 receptor alpha (IL11RA, 5.9-
fold, P = 0.003). The significant expression of all these
genes for the combined suture comparison suggests that
they are likely to be key regulators of morphogenesis in all
sutures.
Unfused sagittal sutures have a lower expression of the 
'unfused' class of genes
To analyse the effect of suture type on gene expression we
used two methods of analysis to compare global expres-
sion data between unfused coronal, sagittal, and lamb-
doid sutures. We then compared results from the two
methods to identify the most robust set of differentially
expressed genes. For the 3-way analysis we used a linear
modelling approach to jointly perform three pair-wise
comparisons: coronal vs sagittal, lambdoid vs sagittal, and
lambdoid vs coronal and we then identified where these
groups overlapped (Fig. 3). This pooled approach pro-
vides greater sensitivity and statistical power over multiple
direct comparisons. Unfused sagittal sutures were found
to have 340 probe sets differentially expressed when com-
Table 4: Gene Ontology analysis: unfused compared to fused 
sutures
Biological process increased in 
sutures:
Unfused Fused P-value
Cell adhesion 32 1.95 × 10-12
Cell matrix adhesion 4 6.53 × 10-3
Cell communication
Cell surface receptor linked signal 
transduction
25 4.45 × 10-3
Dopamine metabolism 2 6.63 × 10-4
Phosphoinsitide-mediated 
signalling
8 4.58 × 10-3
Cell differentiation
Heme biosynthesis 3 6.96 × 10-3
Lymphocyte differentiation 6 1.27 × 10-3
Cellular physiological process
Anion transport 11 4.92 × 10-6
Cell cycle 42 4.72 × 10-5
Cell motility 11 2.70 × 10-4
Extracellular matrix organisation 
and biosynthesis
4 1.11 × 10-3
Microtubule based process 10 7.35 × 10-3
Regulation of phosphorylation 3 5.30 × 10-3
Morphogenesis 18 5.34 × 10-4
Cellular morphogenesis 9 5.60 × 10-3
Mesoderm formation 2 4.46 × 10-3
Organ morphogenesis 8 7.46 × 10-3
Organ development 23 3.45 × 10-7
Cartilage condensation 2 5.89 × 10-3
Eye development 3 4.98 × 10-4
Muscle development 6 2.52 × 10-3
Skeletal development 11 1.18 × 10-6
Regulation of development
Negative regulation of 
development
3 2.28 × 10-3
Response to abiotic stimulus
Response to chemical stimulus 20 7.31 × 10-3
Response to reactive oxygen 
species
3 5.21 × 10-3
Response to biotic stimulus 116 5.73 × 10-41
Defence response to bacteria 11 5.2 x10-9
Defence response to fungi 3 1.65 × 10-3
Response to virus 7 9.11 × 10-3
Immune response 100 1.61 × 10-34
Humoral immune response 22 1.57 × 10-8
Inflammatory response 23 3.08 × 10-7
Classification of gene ontologies (GO) significantly over-represented 
(P < 0.01) for genes at least 2 fold differentially expressed between 
unfused and fused sutures, listed under level 3 GO category headings. 
Not all level three GO categories listed were significantly over-
represented and thus do not have a P-valueBMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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pared to coronal sutures and 323 when compared to
lambdoid sutures, while the coronal and lambdoid
sutures only had 77 probes sets differentially expressed
between each other. Furthermore, 250 of those probe sets
differentially expressed in unfused sagittal were not differ-
entially expressed between the coronal and lambdoid
sutures. This supported the higher correlation of gene
expression of differentially expressed genes between
unfused coronal and lambdoid sutures seen in Figure 2.
Of these 250 probe sets, 62 were increased in unfused
coronal and lambdoid sutures and 188 were decreased,
compared to the sagittal sutures (Fig. 3). The 3-way anal-
ysis also showed that 35 probe sets were uniquely
expressed in unfused lambdoid sutures compared to coro-
nal and sagittal sutures (33 increased and 2 decreased).
To control for patient-specific effects we performed a set
of separate pair-wise comparisons using a matched pairs
design. In this case we first restricted analysis to patients
with a sample from each of the sutures of interest and
then performed analysis on the within patient differences.
A list of significant genes with P < 0.01 was produced from
each pair-wise comparison (Additional files 8, 9, 10).
The combination of the 3-way and pair-wise comparisons
identified 100 probe sets significantly (P < 0.01) differen-
tially expressed in unfused sagittal sutures compared to
unfused coronal and lambdoid sutures. Amongst the top
ten genes, seven had higher expression in unfused sagittal
sutures and two had lower expression compared to coro-
nal and lambdoid sutures (Fig. 4). Outside the top ten,
genes with significantly decreased expression in unfused
sagittal sutures were FGFR2, MSX2, GPC3, and WNT5A,
while the Wnt inhibitor WIF1 had increased expression.
The observed trend was that unfused sagittal sutures have
a lower expression of those genes typically associated with
an unfused suture state and a higher expression of genes
associated with suture fusion (Table 3).
Unfused coronal and sagittal sutures have differential 
expression of transcription factors compared to lambdoid 
sutures
Analysis of the unfused-suture comparison data with
respect to genes differentially expressed by unfused lamb-
doid sutures identified a large number of transcription
factors. Those down-regulated with respect to coronal and
sagittal sutures included FOS,  FOSB,  JUN,  JUNB, and
CART1; all having a tendency for greater expression in the
coronal suture (Table 3). Those genes with higher expres-
sion in unfused lambdoid sutures included transcription
factors FOXD1, MEOX2, HLF and BHLH3.
Microarray results validated by real-time quantitative RT-
PCR and Western blot
Results from the microarray analysis were validated by
qRT-PCR for 11 of the most highly expressed and signifi-
cantly differentially expressed genes: eight genes increased
in unfused suture tissue, RBP4, C1QTNF3, PRELP, GPC3,
PTN,  FMOD,  COL3A1, and COL8A2; and 3 genes
increased in fusing/fused suture tissue, WIF1, ANXA3, and
Venn diagram of 3-way unfused suture comparison results Figure 3
Venn diagram of 3-way unfused suture comparison results. Global expression differences were compared for 3 pair-wise com-
parisons (coronal vs sagittal, lambdoid vs coronal, lambdoid vs sagittal). The sagittal suture showed the greatest difference in gene expres-
sion to the other two sutures, followed by the lambdoid suture. A) Increased genes. 62 genes had similar increased expression in coronal 
and lambdoid sutures compared to sagittal sutures and 33 genes had increased expression in lambdoid sutures and similar expression in 
coronal and sagittal sutures. B) Decreased genes. 188 genes had similar decreased expression in unfused coronal and lambdoid sutures 
compared to unfused sagittal sutures and 2 genes had decreased expression in lambdoid sutures and similar expression in coronal and 
sagittal sutures.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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CYFIP2. The Affymetrix probe set for C1QTNF3 targeted
two transcripts and therefore two transcript-specific prim-
ers sets were designed. Gene expression was analysed
using 10 of the same RNA samples which underwent
microarray analysis (Table 1). A linear correlation was cal-
culated for each transcript for the comparison of expres-
sion values obtained by qRT-PCR and microarray analysis
(Table 5). An average correlation of 90% was observed for
all genes analysed, validating the microarray results. Three
primer sets had a correlation coefficient smaller than
75%; however, two of these primer sets did not amplify all
isoforms detected by their corresponding Affymetrix
probe set. The third primer set was designed to detect the
long isoform of C1QTNF3. While this had a correlation of
74%, the short isoform C1QTNF3 primers had 99% corre-
lation, suggesting that it is the short isoform of C1QTNF3
that is differentially expressed.
Table 5: Linear correlation between microarray and qRT-PCR data.
Gene Probe Set Slope Correlation
ANXA3 209369_at 0.881 0.978
WIF1 204712_at 0.850 0.982
CYFIP2 220999_s_at 0.785 0.748
PTN 211737_x_at 1.063 0.905
PRELP 204223_at 0.755 0.938
FMOD 202709_at 0.867 0.851
C1QTNF3 long isoform 220988_s_at 1.774 0.738
C1QTNF3 short isoform 220988_s_at 0.806 0.990
RBP4 219140_s_at 1.100 0.968
GCP3 209220_at 1.036 0.929
COL8A2 221900_at 1.261 0.854
COL3A1 215077_at 0.767 0.709
Average Correlation 0.896
The average correlation for all probe sets is approximately 90%, not including the correlation of the long isoform of C1QTNF3. The short isoform 
of C1QTNF3 had 99% correlation, indicating that the short and not the long isoform of C1QTNF3 is differentially expressed between unfused and 
fused sutures.
Top ten genes differentially expressed between unfused coronal, lambdoid and sagittal sutures Figure 4
Top ten genes differentially expressed between unfused coronal, lambdoid and sagittal sutures. Genes commonly identified 
to be differentially expressed (P < 0.01) in unfused coronal and lambdoid sutures compared to unfused sagittal sutures, using two meth-
ods of microarray data analysis: 3-way and matched-pairs. Eight genes (FGR, RASGRP2, IGLL1, IL17R, NCF1, APOC1, TACC3, and MKI67) 
have higher expression in unfused sagittal sutures and two (HLF and SLC7A6) have lower expression compared to unfused coronal and 
lambdoid sutures. HLF shows a gradient of expression, highest in lambdoid, then coronal, then sagittal sutures, whereas the other genes 
show similar expression in coronal and lambdoid sutures. For each gene listed, sutures are in patient order: coronal (#36, #46, #50, #58), 
lambdoid (#46, #58), sagittal (#36, #58).BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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To further examine the differential expression of genes
between fused, fusing and unfused sutures identified by
microarray analysis we used qRT-PCR to quantify expres-
sion of all genes noted above using the 10 validation sam-
ples and 25 additional samples from 13 new patients
(Table 1). Although the initial microarray hierarchical
clustering analyses (Fig. 2, Additional file 4) indicated
there was limited difference in whole genome expression
between non-syndromic and syndromic samples, this
analysis only included samples from one syndromic
patient. We therefore extended this comparison by analys-
ing qRT-PCR data obtained from the larger cohort of
patients which included 7 syndromic patients, and 11
non-syndromic patients in total. No significant difference
(P < 0.05) in gene expression was seen between non-syn-
dromic and syndromic samples, when separated into
unfused, fusing, and fused states (Fig. 5A, Additional file
11). This result clearly demonstrates that samples of dif-
ferent aetiologies can be combined to investigate the gen-
eral mechanisms of craniosynostosis.
As the unfused suture samples which underwent microar-
ray and qRT-PCR analyses were obtained from patients
with craniosynostosis, there is the possibility that their
gene expression profiles do not truly represent an unfused
suture from an individual without craniosynostosis. Con-
sequently, the expression of the above mentioned genes
were analysed in unfused coronal, lambdoid, and
metopic sutures obtained from similar age-matched indi-
viduals who were undergoing transcranial surgery for rea-
sons other than craniosynostosis (Table 1). No significant
difference (P < 0.05) in gene expression was observed for
these unfused non-craniosynostosis sutures, compared to
unfused sutures from individuals with craniosynostosis
(Fig. 5B). This provides proof of principle that the analysis
of gene expression profiles from unfused sutures from
craniosynostosis patients is useful in the study of suture
morphogenesis.
qRT-PCR data was then compared between unfused, fus-
ing, and fused samples from each suture site, combing
qRT-PCR expression data comparing syndromic, non-syndromic and non-craniosynostosis samples Figure 5
qRT-PCR expression data comparing syndromic, non-syndromic and non-craniosynostosis samples. A) No significant dif-
ference in expression exists between suture samples from syndromic and non-syndromic craniosynostosis patients. C1QTNF3 is 
decreased during fusion and CYFIP2 is increased during fusion, irrespective of aetiology. Samples from coronal, sagittal, lambdoid, and 
metopic sutures were combined for analysis. Samples numbers (left to right) are n = 8, 4, 5, 4, 7, 7. B) Unfused sutures from craniosynos-
tosis patients (n = 12) and individuals without craniosynostosis (n = 6) show no significant difference (P < 0.05) in expression for all genes 
analysed. Absolute expression values represent molecules per ng cDNA. Mean expression ± SEM is shown.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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non-syndromic and syndromic patients together. Differ-
ential expression profiles were observed for all 11 genes
analysed, although the level of differential expression var-
ied between suture sites (Fig. 6A, Additional file 12). The
greatest difference in expression was observed for coronal
sutures, followed closely by lambdoid sutures, while
metopic sutures had, in general, the smallest changes in
expression between unfused and fused sutures. This later
observation is likely due to the finding that unfused
metopic sutures generally had a lower level of expression
of genes increased in unfused sutures (eg. C1QTNF3,
FMOD and PTN) and a higher expression of genes which
were increased in fused sutures (eg. WIF1 and ANXA3).
Unfused sagittal sutures also showed higher expression
than unfused coronal and lambdoid sutures for those
genes increased in fused sutures (ANXA3 and WIF1) (Fig.
6A). These combined patient results confirmed the suture-
specific analyses outlined earlier (Table 3, Fig. 2). The
qRT-PCR validation experiment also demonstrated a vari-
able gradient of expression between unfused, fusing, and
fused samples for all genes analysed (Fig. 5A and Fig. 6A).
However, this gradient of expression is best analysed
using samples isolated from the same sutures from the
same patient that are undergoing various stages of fusion.
Figure 7 shows the qRT-PCR data from 5 samples isolated
from one Apert syndrome patient (#90). Two fusing coro-
mRNA and protein validation of differential expression identified by microarray analysis Figure 6
mRNA and protein validation of differential expression identified by microarray analysis. A) Real-time qRT-PCR analysis of 
six genes with increased expression in unfused sutures (RBP4, GPC3, C1QTNF3 short isoform, FMOD, PRELP, and PTN) and three genes with 
increased expression in fused sutures (WIF1, ANXA3, and CYFIP2) for unfused, fusing and fused suture tissue isolated from sagittal, coro-
nal, lambdoid and metopic sutures. Significant differential expression (P < 0.05, *; P < 0.01, **) was analysed for fusing and fused sutures 
compared to unfused sutures. Mean expression + SEM is shown; n = 3 for all comparisons, except fused sagittal (n = 5), fused metopic (n 
= 4), and fused lambdoid (n = 2). Absolute expression values represent molecules per ng cDNA. B) Western blot analysis of individual 
protein samples in the order seen in (C), for collagen type 1 (COL1), GPC3, C1QTNF3 and RBP4. C) Densitometry analysis of western 
blots normalised to COL1 expression.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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nal samples were isolated from this patient, one during
the early stages and one during the later stages of fusion,
along with a fully fused coronal suture and unfused sagit-
tal and metopic sutures. The data shows that ANXA3 and
CYFIP2  are increased in fusing sutures, but are further
increased in fully fused sutures, whereas WIF1 has the
greatest expression in fusing sutures and is slightly
decreased once the suture is fully fused, however this level
remains above unfused sutures. This subtle difference can-
not be seen in Figure 6A where fusing sutures of different
stages from different patients are grouped together. Figure
7 also again highlights the difference in expression of
unfused metopic sutures, being closer in expression to fus-
ing sutures than other unfused sutures for a number of
genes.
Differential protein expression was assessed by Western
blot analysis for three genes with increased expression in
unfused sutures, RBP4, C1QTNF3 and GPC3 (Fig. 6B and
6C). Microarray results indicated that collagen type I
alpha 2 was the most abundant transcript and was not dif-
ferentially expressed between unfused and fused suture
tissues (1.05 fold, Table 3). Protein expression was there-
fore normalised to COL1 for comparative quantification.
All three proteins were differentially expressed in a similar
pattern to that observed for the RNA expression data, with
a decreasing gradient of expression observed for unfused,
fusing, and then fused samples. Again, lower expression of
each protein was observed in unfused metopic sutures.
Higher protein expression was observed in two fused sag-
ittal sutures (#46 and #58) compared to two other fused
sagittal sutures (#50 and #60). This may be explained in
part by tissue structure. During sample preparation it was
noted that #46 and #58 sutures were very thin, flat bones
more representative of developed calvaria, while #50 and
#60 were more archetypal, having enlarged fused-suture
ridges [5].
Unfused Lambdoid sutures express cartilage-specific 
markers
Increased expression of COL10A1 and COL2A1 was iden-
tified in unfused lambdoid sutures and one (#58) of the
two unfused sagittal sutures compared to all other sam-
ples (Table 3). The unfused sagittal suture from patient
#58 was taken from the extreme posterior portion of the
suture very close to the lambdoid suture (Fig. 1A). In all
other gene expression analyses this sample grouped with
the other unfused sagittal suture, verifying its correct clas-
sification as sagittal suture tissue. The expression of carti-
lage-specific collagens suggested, contrary to conventional
thinking, that cartilage may play a role in human suture
morphogenesis. Histological analysis of fused and
unfused lambdoid, coronal, and sagittal sutures from
additional patients to those used for microarray analyses
(Table 1), identified cartilage only in unfused lambdoid
sutures (Fig. 8). Cartilage was found at the tips of the oste-
Within patient comparison of gene expression in fused, fusing, and unfused sutures Figure 7
Within patient comparison of gene expression in fused, fusing, and unfused sutures. Gene expression was analysed in five 
suture samples from an Apert syndrome patient (#90) by qRT-PCR. A gradient of expression is seen for all genes from unfused sagittal 
(US), to unfused metopic (UM), early fusing coronal (FgEC), late fusing coronal (FgLC), and fused coronal (FC) sutures. ANXA3 and CYFIP2 
are increased highest in fused sutures, WIF1 in fusing sutures and all other genes have highest expression in unfused sagittal sutures. 
Unfused Metopic sutures show higher expression of genes increased during fusion and a lower expression of genes increased in other 
unfused sutures. Absolute expression values represent molecules per ng cDNA. Error bars represent SEM for triplicate technical repli-
cates.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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ogenic fronts which protruded into the suture mesen-
chyme. This cartilaginous region was composed of what
histologically appeared to be a region of proliferating and
hypertrophic chondrocytes, and was seen to protrude into
the osteoblastic region where calcification was occurring
to form calvarial bone (Fig. 8A–8F). The spatial expres-
sion of COLX protein, which is a specific marker of hyper-
trophic chondrocytes [41], was investigated by confocal
immunofluorescence (Table 1). COLX was found to be
highly abundant in osteoclasts, which were localised to
the edges of the cartilage matrix adjacent to the bone
matrix. COLX was also expressed, but more weakly, by
chondrocytes in the cartilage matrix (Fig. 8I, J). COLX
expression was not identified in any other suture type
(Fig. 8K).
Different spatial localisation of RBP4 and GPC3 in unfused 
sutures
Tissue localisation of RBP4 and GPC3 was investigated
using confocal microscopy in fused and unfused tissue
from coronal, sagittal, and lambdoid sutures (Fig. 9). In
all unfused sutures, RBP4 was located in the cytoplasm,
the most intense staining being in osteocytes in the outer-
most region of bone overlying the suture region on the
ectocranial but not the endocranial surface (Fig. 9A, B, E).
RBP4 expression was also observed in osteoblasts at the
osteogenic fronts (Fig. 9C, D), those invaginating the oste-
Cartilage localisation in unfused sutures Figure 8
Cartilage localisation in unfused sutures. A-B) Serial H&E and Alcian blue stain of right unfused lambdoid suture (#83) showing car-
tilage (boxed regions expanded in panels E and F, respectively) on either side of suture mesenchyme (m). C) Alcian blue stain of left 
unfused lambdoid suture (#83) showing cartilage fronts (box) surrounding suture mesenchyme. D) Cartilage front from panel C (box) 
showing proliferating (stacked cells) and hypertrophic (cells with enlarged lacunae) chondrocytes in a cartilage (c) matrix. E-F) Enlarged 
views of boxed regions in A and B, respectively showing H&E (E) and Alcian blue (F) stain of right unfused lambdoid suture (#83) and 
highlighting cartilage interspersed with calcified bone (b, dark pink). Hematoxylin stains calcified matrix darker. G-H) Serial H&E (G) and 
Alcian blue (H) staining of an unfused coronal suture (#83) showing no staining of cartilage in (H). I-J) H&E (I) and confocal immunofluo-
rescence for Collagen type X (J) detected weak localisation (orange) in hypertrophic chondrocytes (ch), with intense (yellow) punctate 
localisation in osteoclasts (multi-nucleated cells, arrowhead) adjacent to the cartilage matrix of unfused lambdoid sutures (#83). K) Col-
lagen type X protein was not detected in osteogenic fronts of unfused coronal sutures (#83). Magnification: A-C, G-H: X3.2; D-F: X12.5; 
Scale: I-K: 10 μm.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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oid, and by osteocytes at the bone margin (Fig. 9F, G), but
not in osteocytes distal from the suture region. In the
lambdoid sutures, RBP4 expression was also high in oste-
oblastic cells lining the cartilage fronts. No specific stain-
ing was observed in fused sutures (Fig. 9H).
Glypican 3 was most highly expressed in suture mesen-
chyme, particularly adjacent to the osteogenic fronts.
There was distinct cell surface staining of mesenchymal
cells, clearly showing the delicate branching of their cyto-
plasmic extensions, forming an interlacing network
throughout the suture space between bone fronts (Fig.
9J–L). Osteoblasts lining osteogenic fronts and those
recently invaginated also had membranous staining
although considerably weaker. There was also staining of
mesenchymal cells close to the tissue surface in the mid-
Localisation of RBP4 and GPC3 in suture tissue Figure 9
Localisation of RBP4 and GPC3 in suture tissue. A-B) Immunofluorescence and H&E stain showing intense localisation (yellow) of 
RBP4 in the cytoplasm of osteocytes (oc) in ectocranial surface bone (unfused coronal suture, #83). C-D) Serial immunofluorescence (C) 
and H&E sections (D) showing RBP4 located in cells in the region between calcified tissue (b) and mesenchyme (m) (unfused left lambdoid 
suture, #83). E) RBP4 was not detected on the endocranial surface of unfused sutures (coronal, #83). F) RBP4 was localised to the cyto-
plasm of osteoblasts (ob) lining the developing bone, those being trapped in the osteoid (arrow head), and osteocytes (unfused coronal 
suture, #83). G) Corresponding phase contrast image to the central region in (F). H) RBP4 was not detected in fused sutures. Red blood 
cells had weak autofluorescence (sagittal, #5). I-L) GPC3 immunofluorescence (I) and H&E (J) detected protein in mesenchymal cells 
close to the tissue surface (arrow head) in the mid-suture region (unfused sagittal suture, #5). Membrane staining was observed for the 
cytoplasmic extensions of mesenchymal cells adjacent to calcified bone (K-L, unfused coronal suture, #83). J) H&E of section deep to (K) 
showing calcified bone protruding into intervening mesenchyme with osteoblasts lining the bone. Scale: 10 μmBMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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sutural region (Fig. 9I). The higher expression in mesen-
chymal cells correlates with the higher mRNA and protein
expression in unfused compared to fusing and fused
sutures (Fig. 6).
Discussion
Here, we have identified novel genes and attempted to
gain a broader understanding of the various molecular
pathways controlling suture morphogenesis in humans
postnatally by analysing global gene expression differ-
ences between unfused sutures and prematurely fusing/
fused sutures from patients with craniosynostosis. This is
the first study in which microarray analysis has been
applied to investigate differential gene expression in
fused, fusing, and unfused human sutures. We identified
differentially expressed genes in pathways that have been
a major focus of study in craniosynostosis, including FGF,
TGFβ and EGF signalling pathways. In addition, we iden-
tified genes from the Eph/ephrin pathway that has
recently been linked with craniosynostosis [32,33] and
the Wnt pathway that is involved osteoblast differentia-
tion [42] and transducing FGFR signals [43]. A number of
novel genes which may have important roles in suture
biology and which have not been previously linked with
craniosynostosis have also been identified, specifically
RBP4,  GPC3, and C1QTNF3. All three are abundantly
expressed in unfused sutures and are significantly down-
regulated in prematurely fused sutures.
A role for retinol binding protein 4 in regulating retinoic 
acid induced osteoblast differentiation
Retinol binding protein 4 (RBP4) expression was decreased
37-fold in prematurely fused/fusing sutures compared to
unfused sutures by microarray analysis. RBP4 is a secreta-
ble plasma protein that classically transports retinol from
liver stores to tissues where it undergoes catalytic conver-
sion into retinoic acid (RA) [44]. Extrahepatic RBP4
expression occurs in adipose, kidney, cartilage, and brain
tissue and during embryonic development of the orofacial
region [45-48]. It has been speculated that tissue-specific
expression of RBP4 is linked to the binding of retinol from
plasma in the immediate vicinity of, and for specific use
by, its tissue of origin [49,50]. Our finding of RBP4 in
osteocytes on the ectocranial surface of bone directly over-
lying the suture mesenchyme and by cells lining the oste-
ogenic fronts, and its dramatic downregulation in suture
fusion now implicates a role for it in suture morphogene-
sis and craniosynostosis. At teratogenic levels, the metab-
olite of retinol, RA, causes craniosynostosis and other
developmental anomalies [4,51,52]. At physiologic levels,
however, RA represses growth of preosteoblastic cells and
enhances the expression of alkaline phosphatase, osteonec-
tin, osteopontin, collagen type I and the osteoblast specific
transcription factor RUNX2 [53,54]. RA also stimulates
BMP2 expression and cooperates to induce osteoblast dif-
ferentiation [55]. Furthermore, primary rat calvarial oste-
oblasts treated with RA have increased osteopontin
expression and switch from predominately expressing
FGFR2 to FGFR1, representing a switch from active prolif-
eration to osteoblast differentiation [56]. At physiologic
levels, a function of this metabolite of retinol is therefore
to suppress preosteoblastic proliferation and activate dif-
ferentiation. This role of RA correlates with the localisa-
tion, reported here, of RBP4, the specific transporter of its
precursor, in cells lining the ectocranial surface and the
osteogenic fronts of unfused sutures and in those recently
invaginated into the osteoid. RBP4 may therefore repre-
sent a primary regulator of osteogenesis in calvarial
sutures by mediating the availability of retinol and its sub-
sequent conversion to RA. In support of this, RBP4 knock-
out mice develop cranial malformations [57]. Taken
together with our data on RBP4 expression during suture
fusion and epidemiological evidence linking excess RA
with craniosynostosis and other developmental anoma-
lies [4,51,52,58] we speculate that perturbations in the
RBP4-retinol-RA axis may contribute to the occurrence of
craniosynostosis.
A role for glypican 3 in maintaining suture patency
Glypican 3 (GPC3) is a cell surface heparan sulfate prote-
oglycan which binds to the extracellular surface of cells via
a GPI (glycosyl-phosphatidyl-inisotol) anchor and is
thought to facilitate interaction between various ligands
and receptors. Loss-of-function mutations in GPC3 cause
Simpson-Golabi Behmel syndrome (MIM 312870), an
overgrowth syndrome with multiple skeletal abnormali-
ties (large protruding jaw, widened nasal bridge, upturned
nasal tip, and broad, short hands and fingers) that is asso-
ciated with increased cell proliferation [59]. Our study
shows that GPC3 expression is decreased 7-fold in prema-
turely fused/fusing sutures. GPC3 interacts with FGF2,
WNT5a, and BMP-4 and -7 which are ligands of FGF
receptors, WNT receptors (FZDs), and BMP receptors,
respectively [60-62], all of which have been variously
implicated in regulating osteoblast function. Molecular
studies show that loss of GPC3 enhances the limb pattern-
ing defect of BMP4 heterozygous mice [62] and that GPC3
can bind FGF2 and suppress FGF2-induced cell prolifera-
tion [61]. GPC3 is also able to regulate the Wnt signalling
pathway. GPC3 knockout mice exhibit an inhibition of
the non-canonical Wnt/JNK signalling pathway, and acti-
vation of the canonical Wnt/β-catenin signalling pathway
[63]. Canonical Wnt/β-Catenin signalling promotes oste-
oblast differentiation and bone accrual and inhibits oste-
oblast apoptosis (reviewed in [39]). We speculate that
GPC3 controls cell growth within suture mesenchyme by
regulating the bioavailability of FGFs, BMPs, and Wnts
and might therefore acts as a gate-keeper of cell respon-
siveness in the suture.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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A role for C1QTNF3 in suture morphogenesis
C1QTNF3 (C1q tumor necrosis factor related protein 3),
also known as CTRP3/cartducin, and CORS26, is a growth
factor that hitherto had not been linked to suture mor-
phogenesis. Our microarray study showed that C1QTNF3
expression is decreased 20-fold in prematurely fused/fus-
ing sutures and qRT-PCR analysis determined that it is the
short isoform of C1QTNF3 that is differentially expressed
(Table 5, Fig. 6A). C1QTNF3 regulates proliferation of
chondrocytes and their progenitor cells during both post-
natal and embryonic development and has been shown to
be up-regulated during BMP2 and insulin induction of
chondrocyte differentiation [64]. C1QTNF3 has also been
identified as promoting proliferation and migration of
mouse endothelial MSS1 cells [65]. With the discovery of
C1QTNF3 expression in unfused and fusing tissue of all
sutures (Fig. 6), we predict a novel role for this growth fac-
tor in the regulation of osteoprogenitor proliferation and
differentiation at the osteogenic fronts. Given our finding
of cartilage-specific markers associated with posterior
skull sutures we speculate that C1QTNF3 might also be
involved in chondrogenesis in addition to osteogenesis in
these sutures.
The identification of cartilage in posterior sutures
Of particular interest was the identification in our micro-
array experiment of increased expression of genes coding
for cartilage-specific collagens types II and X  in the two
unfused lambdoid and the unfused sagittal sutures from
the posterior of the skull. The involvement of cartilage in
unfused lambdoid sutures was confirmed histologically
through the observation within the region of the osteo-
genic fronts of a cartilaginous matrix which protruded
into the suture mesenchyme and adjacent calcified bone
matrix (Fig. 8). In addition, confocal microscopy localised
collagen type X to chondrocytes in the cartilage matrix and
in osteoclasts adjacent to cartilage (Fig. 8I, J). Identifica-
tion of what is termed 'secondary cartilage' has been pre-
viously noted in several human calvarial sutures, with a
high incidence in normal lambdoid sutures [66,67]. It has
been proposed that this secondary cartilage may develop
in response to the higher mechanical forces applied to the
posterior region of the skull during growth as it provides
a matrix more tolerant to compression [5]. Cartilage has
also been observed in rodent sutures where a cartilaginous
plate underlies the lambdoid suture, possibly forming a
supportive structure on which intramembranous ossifica-
tion occurs [24]. Recently, cartilage and chondrocytic
markers have also been identified in sagittal sutures of
transgenic mice generated with the Apert syndrome
FGFR2 S252W mutation [68]. The cartilage was located at
the junction of the parietal and interparietal bones which
corresponds to the region from which the sutures we iden-
tified as expressing cartilage-specific genes were isolated.
Importantly, we demonstrated that cartilage is present
within the osteogenic fronts, rather than underlying the
sutures suggesting a functional rather than supportive
role. Recently, Sox9, a regulator of chondrogenesis, has
been shown to be upregulated during the initiation of
posterior frontal suture closure in mice, along with the
expression of collagen types II and X, followed by collagen
type I and osteocalcin expression [69]. A role for endochon-
dral ossification was therefore proposed to control fusion
of this suture. Additionally, collagen types II and aggrecan
have been detected in preosteogenic-condensing mesen-
chyme and the osteogenic fronts of developing embryonic
chick heads [70]. It was proposed that, in chickens, nor-
mal intramembranous ossification includes a transient
chondrogenic phase. The identification, in our study, of
cartilage in lambdoid suture mesenchyme also suggests
that chondrogenesis plays a role in human suture mor-
phogenesis, particularly in the posterior skull.
Distinctive tissue-type specific gene expression differences
The analysis of gene expression in the different suture-
types indicated that gene expression profiles of unfused
metopic sutures were more highly correlated with the
expression exhibited by fused sutures from other suture
sites; specifically they showed a significantly lower expres-
sion of those genes increased in other unfused sutures
(Fig. 6A, 7). This unique expression profile may help
explain the earlier occurrence of metopic suture fusion
during development. Unfused coronal and unfused lamb-
doid sutures also showed very similar expression profiles.
Both these sutures are generally formed by overlapping
calvarial bone fronts, in comparison to the blunt-end
sutures which form the sagittal and metopic sutures [5].
These sutures are also similar in that they are a meeting of
bones of two different developmental origins (mesoderm
and neural crest cells) while the sagittal and metopic
sutures are the meeting point of bones of one origin,
either mesoderm or neural crest, respectively.
Transcription factors are key controllers of the signalling
cascades activated during development. Of those tran-
scription factors differentially expressed between fused
and unfused suture tissue a majority also showed signifi-
cant expression differences between suture types. Unfused
sagittal sutures had a higher expression of homeobox
genes SHOX2 and PAX5 which potentially drive osteob-
last differentiation and generally had increased expression
in fused sutures. The unfused sagittal sutures also showed
a lower expression of MSX2, SIX2, PITX2, BHLH3, and
HLF  that were generally increased in other unfused
sutures compared to fused sutures. Given the higher fre-
quency of non-syndromic craniosynostosis in the sagittal
suture we speculate that a lower expression of transcrip-
tion factors associated with unfused sutures, and a higher
expression of those associated with fused sutures, might
leave this suture more vulnerable to premature closure.BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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Both unfused sagittal and unfused coronal sutures had
significantly higher expression of members of the FOS
(FOS and FOSB) and JUN (JUN  and JUNB) oncogene
families compared to unfused lambdoid sutures, particu-
larly for coronal sutures (eg. FOSB was 54.4-fold increased
in the coronal sutures, compared to 20.2-fold in the sagit-
tal sutures). Through homo- and hetero-dimerisation,
these proteins form the AP-1 transcription complex.
Increased Jun and Fos expression occurs in prematurely
fused mouse sutures induced by the application of FGF2-
soaked beads [71]. It was suggested that FGF signalling
increases expression of the AP-1 complex which then
induces expression of osteopontin and osteoblast differ-
entiation, resulting in premature suture closure. It is also
known that the coronal and sagittal sutures are those most
frequently affected in FGFR syndromic craniosynostoses.
We therefore suggest that the higher expression of AP-1
transcription factor components in coronal and sagittal
sutures makes them more responsive to the increased or
inappropriate FGF signalling caused by gain-of-function
FGFR  mutations. However, it was also observed that
unfused sagittal sutures had decreased expression of
FGFR2 compared to the coronal suture. This may explain
why mutations in these genes most commonly affect the
coronal suture rather than the sagittal suture.
Another important finding from our microarray analysis
was that there was limited difference in whole genome
expression between non-syndromic and syndromic
patient samples. This was verified by qRT-PCR using 35
samples from 7 syndromic and 11 non-syndromic
patients, analysing 11 genes differentially expressed
between unfused and fused sutures. We note, however,
that these genes were identified as being significantly dif-
ferentially expressed during premature fusion by using tis-
sue groups which contained samples from patients with
different aetiologies. Thus, we specifically identified genes
which were not specific to one aetiology. If these two
groups of samples were analysed independently, it is
likely that there may be a small proportion of genes which
are differentially expressed between samples from
patients with different aetiologies and these genes will be
directly related to the mutation of initiation. However, in
this study we were not so interested in these aetiology spe-
cific indicators, but rather the general mechanisms under-
lying craniosynostosis. Significantly, the results from our
microarray hierarchical analysis study indicate that the
genes involved in the pathogenesis of different types of
craniosynostosis are more similar than may previously
have been thought.
Conclusion
Through the analysis of human suture material we have
identified a large number of novel differentially expressed
genes, three of which, RBP4, GPC3  and C1QTNF3, we
believe may have significant regulatory roles in the con-
trol of both suture patency and growth. Furthermore, we
have identified significant gene expression differences
between human sutures from different cranial sites and
identified the involvement of cartilage in posterior calvar-
ial sutures, particularly the lambdoid suture. These data
open up new avenues of investigation in respect to the
molecular mechanisms underlying the different responses
of calvarial sutures to mutations causing craniosynostosis.
This information is vital for the development of therapeu-
tic agents to control skull growth in children with sutural
defects, as well as providing clinicians with a better under-
standing of the developmental mechanisms operating in
different sutures.
Methods
Tissue Samples
Calvarial suture samples were obtained from patients
undergoing transcranial surgery for syndromic or non-
syndromic craniosynostosis. Patients were genotyped for
all known FGFR1-3 and TWIST1  mutations (Table 1)
[72]. Samples used for microarray analysis (n = 16) were
taken from males (n = 5) aged 3-7 months. Additional
samples used for validation experiments (n = 25) and his-
tology (n = 9) were taken from female (n = 8) and male (n
= 10) patients aged 3-40 months. Additionally, six
unfused suture samples were obtained from patients aged
1 day to 91 months undergoing transcranial surgery for
reasons other than craniosynostosis (Table 1). Consent
was provided by all guardians in line with the guidelines
of the Research Ethics Committee of the Children, Youth
and Women's Health Service, Adelaide, South Australia.
Suture tissue was taken from prematurely fused/fusing
and/or patent sutures from one or more of the sagittal,
coronal, lambdoid, and metopic sutures. The site and
fusion state of samples used for each analysis type are
indicated in Table 1. Specimens used for microarray anal-
ysis and validation experiments were stored in RNAlater
(Ambion, Austin, TX, USA) at -20°C. Specimens used for
histology and immunofluorescence were fixed in forma-
lin, decalcified with 10% EDTA, pH 7.4, by standard pro-
cedures and stored in 100% ethanol.
3DCT and MicroCT scans
Stage of fusion was confirmed by assessing 3D computer
tomography (CT) images taken prior to surgery. Selected
suture samples underwent MicroCT analysis to determine
the degree of fusion, as previously described [73]. Briefly,
tissues samples were placed in RNAlater, enclosed tightly
in an acrylic tube, and analysed with a SkyScan 1072
MicroCT scanner (SkyScan, Antwerp, Belgium). 2D
images were used to generate 3D reconstructions using 3D
creator software (SkySkan).BMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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Total RNA isolation
Tissues used for microarray analysis and validation exper-
iments had the suture proper (suture mesenchyme + 3
mm bone on either side for unfused sutures, or fused
bony ridge + 3 mm bone on either side for fused sutures)
dissected from all specimens and the overlying pericra-
nium was removed. Tissue samples were cut into 30-40 μg
pieces for RNA extraction, snap frozen, crushed between
cryogenically cooled steel blocks, and homogenised in 2
ml TRIreagent (Molecular Research Center, Cincinnati,
OH, USA) using a Mini-Bead-Beater-8 (BioSpec Products,
Bartlesville, OK, USA). RNA was isolated from superna-
tant following recommendations by Naderi et al. [74].
Briefly, separated aqueous phase was twice extracted with
chloroform and precipitated with 1 volume isopropanol,
0.1 volume 7.5 M ammonium acetate, and 5 μg/ml linear
polyacrylamide (Ambion) at -20°C overnight. Pelleted
RNA was washed twice with 70% ethanol and resus-
pended in RNA Storage Solution (Ambion). RNA extracts
from the same sample were combined. 10 μg of each com-
bined RNA sample was purified and concentrated to
greater than 300 ng/μl with phenol:chloroform:isoamyl
alcohol (25:24:1) extraction. Total RNA quality was deter-
mined by analysing the integrity of the 28S and 18S ribos-
omal bands on a non-denaturing 1.5% agarose Tris-
borate buffered gel and determining RNA purity by
A260:280 ratios using UV spectroscopy.
Microarray cDNA synthesis, hybridisation, and scanning
RNA from 16 tissue samples (Table 1) was analysed using
the Affymetrix expression microarray Human U133A 2.0
GeneChip platform. Concentrated total RNA was pre-
pared for hybridisation to the GeneChips following a one-
cycle target labelling protocol (Affymetrix GeneChip
Expression Analysis Technical Manual). RNA was reverse
transcribed into double stranded cDNA using SuperScript
II (Invitrogen, Gaithersburg, MD, USA) with T7-oligom-
ers. Poly-A RNA spike-in controls were added along with
2 μg of total RNA to all cDNA reactions. Biotin labelled
cRNA was prepared from the cDNA using the GeneChip
IVT labelling system (Affymetrix, Santa Clara, CA, USA),
with incubation at 37°C for 16 hours. 10 μg of frag-
mented cRNA was hybridised to each Affymetrix U133A
2.0 GeneChip. Array hybridisation, staining, and washing
was carried out following manufacture's protocols using
the Fluidics Station 400 (Affymetrix). Stained arrays were
scanned on a GeneChip Scanner 3000 (Affymetrix) con-
trolled by GCOS software (Affymetrix).
Microarray data analysis
CEL files containing probe intensity data were analysed in
R using Bioconductor packages [75,76]. Quality control
analyses were carried out on probe level model (PLM)
normalised samples. Normalised un-scaled standard error
(NUSE) box plots, Mbox plots, and RNA degradation
plots were analysed [77]. For statistical analyses probe
intensity data were normalised using the GeneChip
Robust Multichip Average (GCRMA) algorithm, which
has been shown to provide a good balance between accu-
racy and precision [78]. Diana-divisive hierarchal cluster-
ing was used to cluster the microarray samples based on
whole genome expression values. To identify differential
gene expression the Limma package was used to fit linear
models to the data, incorporating an empirical Bayes
modification of the standard errors [79]. False discovery
rate adjustment of P-values was performed to account for
multiple testing [80]. Correlation plots and hierarchal
trees were generated using cluster packages available in R.
Gene ontology over-representation was analysed using
GOTree Machine, normalising to the U133A 2.0 gene set,
with significance set at P < 0.01 [81,82]. Gene set enrich-
ment analysis was carried out using GSEA v 2.01, compar-
ing the ranked list of 2-fold differentially expressed probe
sets to gene sets c1-c4 (v2.symbols.gmt) [83,84]. Gene set
exclusion was set at min = 4, max = 500, with 1000
weighted permutations executed. A 3-way contrast matrix
was created for the unfused suture comparisons: coronal-
sagittal, lambdoid-sagittal, and lambdoid-coronal. Using
the Limma package a Venn diagram was produced for
those genes identified to be differentially expressed using
a nested F-test approach which gives particular attention
to genes which are differentially expressed (P  < 0.01)
under 2 or more conditions. To control for patient-spe-
cific effects due to the small sample size of this compari-
son, we performed a set of separate pair wise comparisons
using a matched pairs design. In this case we first restricted
analysis to patients with a sample from each of the sutures
of interest, and then performed analysis on the within
patient differences. A matched-pairs matrix was con-
structed for an unfused coronal-lambdoid comparison
using samples from patients #36 and #46 and a coronal
and sagittal comparison using samples from patients #36
and #58. A t-test was performed between unfused lamb-
doid and sagittal samples from patients #36, #46 and #58.
A linear model incorporating an empirical Bayes modifi-
cation was applied to each matched pairs comparison. To
identify genes differentially expressed in unfused sagittal
sutures, the intersection of the 3-way and matched pairs
coronal-sagittal comparison and lambdoid-sagittal com-
parisons was found.
Realtime quantitative RT-PCR (qRT-PCR)
Total RNA was reverse transcribed into cDNA using Super-
Script III (Invitrogen). Two micrograms of RNA was added
to 40 μl total volume reactions which were carried out fol-
lowing the manufacturer's protocol. In addition to the
patient RNA samples, a calibrator RNA sample which was
used to standardise absolute qRT-PCR results, was tran-
scribed into cDNA, column purified (QIAquick PCR puri-
fication kit, Qiagen, Clifton Hill, VIC, Australia) andBMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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quantified by UV spectroscopy. cDNA from all samples
was diluted 1/3 and 1/120 with TE (pH 8) and supple-
mented with herring sperm DNA to 1 ng/μl. The 1/120
dilutions were used for the amplification of the 18S rRNA
gene and the 1/3 dilutions were used for the analysis of all
other genes. Absolute quantification was carried out using
standard curves generated by serial dilution of target
amplicon-containing plasmids (pGEM-T easy, Promega,
Annandale, NSW, Australia), to cover up to 5 logs of
amplicon copy number per microlitre. All primers were
designed to target the same sequence as the microarray
probes, to overlap exon-exon junctions, and to have a
melting temperature of 60°C (Additional file 13). Real-
time reactions were carried out using SYBR green (Applied
Biosystems, Foster City, CA, USA) on a ABI Prism 7000
Sequence Detection System (Applied Biosystems). Twenty
microlitre reactions contained 2 μl of cDNA and 0.4 μM
each primer. PCR amplification followed a two step
cycling protocol; 10 min denaturation at 95°C followed
by 40 cycles of 95°C for 15 s and 60°C for 1 min. Melting
curve analysis was conducted to confirm specific ampli-
con amplification. Patient reactions were performed in
triplicate and standard curve points in duplicate. ABI
Sequence Detection Software version 1.2 was used to
determine sample Ct values, with the same threshold set
for all reactions. Absolute copy number values calculated
from standard curves were normalised to a calibrator
cDNA sample (1 ng was used for RT-PCR) by calculating
a ratio of the patient 18S Ct to that of the calibrator sam-
ple 18S Ct. Differences between samples were analysed for
log10 transformed data by Student's t-test, with signifi-
cance set at P < 0.05.
Western blot analysis
Whole tissue protein was isolated from the TRIreagent
organic phase separated during RNA extraction following
the manufacturer's instructions and reconstituting in 10
M urea. Protein was quantified using the Bio-Rad Protein
Assay (Bio-Rad, Regent Park, NSW, Australia) and 25 ng of
total protein was resolved by 10% SDS-PAGE and trans-
ferred to a Hybond-C nitrocellulose membrane (Ammer-
sham, North. Ryde, NSW, Australia). Membranes were
blocked with Odyssey Blocking Buffer (LI-COR Bio-
sciences, Lincoln, NE, USA) diluted 1:1 in TBS (50 mM
TRIS pH 7.5, 150 mM NaCl) for 45 min. Antibodies were
diluted 1:1 in blocking buffer with 0.1% Tween-20.
Blocked membranes were probed with either mouse mon-
oclonal anti-collagen type I (COL1, 1:100, Calbiochem,
Alexandria, NSW, Australia) or goat anti-mouse CORS26/
C1qTNF3 (1:50, R&D Systems, Minneapolis, MN, USA)
and incubated overnight at 4°C. COL1-probed mem-
branes were double probed with rabbit polyclonal anti-
human retinol-binding protein (RBP4, 1:20000, DAKO,
Botany, NSW, Australia) for 1 h at room temperature
(RT). Membranes were washed three times in TBST (50
mM TRIS pH 7.5, 150 mM NaCl, 0.1% Tween-20) follow-
ing primary antibody incubation. Antibody binding to
double probed membranes was detected by infrared emis-
sion using goat anti-rabbit Alexa Flour 680 (1/20000,
Molecular probes, Eugene, OR, USA) and goat anti-mouse
IRDye 800 (1:15000, Rockland, Gilbertsville, PA, USA).
Antibody binding to single probed membranes was
detected with donkey anti-goat Alexa Fluor 680 (1:10000,
Molecular Probes). Protein bands were detected and
quantified using the Odyssey infrared imaging system (LI-
COR Biosciences). Double probed membranes were
stripped with low pH stripping buffer (25 mM glycine-
HCL pH 2, 1% (w/v) SDS) for 30 min at RT, followed by
washing in TBST. Stripped membranes were blocked in
5% skimmed milk in TBST for 30 min. Membranes were
probed with primary sheep anti-human glypican 3
(GPC3, 1:2000, R&D Systems), followed by rabbit anti-
sheep horseradish peroxidase-conjugated antibody
(1:2000, Chemicon) and Immobilon Western Substrate
(Millipore, North Ryde NSW, Australia). Antibodies for
GPC3 detection were diluted in 5% skimmed milk in
TBST and incubated for 1 h at RT. For densitometry, GPC3
blots were scanned using the Odyssey imaging system (LI-
COR Biosciences).
Immunofluorescence confocal microscopy
Fixed and decalcified specimens were dehydrated through
a graded ethanol series and embedded in paraffin. Sec-
tions were cut to 3 μm thickness, mounted on 3-aminot-
riethoxysilane (APES)-coated slides and incubated for 16
h at 60°C, followed by 7 h at 37°C. Sections were depar-
affinised and rehydrated in distilled H2O for 5 min. Anti-
gen retrieval was carried out using TEG buffer (TRIS-
EGTA, pH 9.0) for RBP4 and COLX and TRIS-HCl buffer
(pH 1.0) for GPC3. All sections were incubated at 60-
70°C overnight with constant stirring. Slides were cooled
and washed in 1 × PBS (pH 7.4) before incubating in
blocking buffer (0.3% casein, 0.1% Tween-20, in 1 × PBS
pH 7.4) for 15 min. Rabbit polyclonal anti-human RBP4
(1:2000, DAKO), sheep anti-human GPC3 (1:50, R&D
Systems), and mouse monoclonal anti-collagen type X
(COLX, 1:500, Sigma-Aldrich, Castle Hill, NSW, Aus-
tralia) primary antibodies were incubated for 1 h, fol-
lowed by washing in 1 × PBS and Tween 20 (0.1%).
Sections were incubated with corresponding secondary
antibodies (goat anti-rabbit Alexa Fluor 488, donkey anti-
sheep Alexa Fluor 488, goat anti-mouse Alexa Flour 488)
for 1 h at RT followed by washing. All antibodies were
diluted in 1 × PBS. Sections were coverslipped using Pro-
Long Gold antifade (Invitrogen) and viewed with a Leica
TCS 4D confocal laser scanning microscope (Leica Laser
Technology, Heidelberg, Germany). Secondary antibodies
was excitated with a 488-nm laser and fluorescent light
detected using a FITC band pass 520-560 nm barrier filter.
The controls were prepared in the absence of the primaryBMC Genomics 2007, 8:458 http://www.biomedcentral.com/1471-2164/8/458
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and the secondary antibodies, and with both antibodies
but without antigen retrieval, and were negative in all
cases.
Histology and cartilage detection
Decalcified formalin fixed specimens were sectioned (3
μm), mounted onto APES-coated slides, and incubated at
60°C for 16 h. Deparaffinised and rehydrated sections
were stained with 1% Alcian blue in 3% aqueous acetic
acid (pH 2.5) to detect the presence of cartilage, or hema-
toxylin and eosin for tissue structure, and mounted in
Depex (Sigma-Aldrich). Sections were imaged using a
brightfield microscope (Carl Zeiss Jena, Jena, Germany)
equipped with a DFC480 digital camera (Leica Microsys-
tems).
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between fusing/fused and unfused suture tissue. A positive value indicates 
higher levels in fused sutures and a negative value indicates higher expres-
sion in unfused sutures.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-458-S5.xls]
Additional file 6
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